REG - Oxford Biomedica PLC - PDMR Dealing

Oxford BioMedicaAnnouncement

07/10/2022 12:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221007:nRSG2105Ca&default-theme=true

RNS Number : 2105C  Oxford Biomedica PLC  07 October 2022

 

 

PDMR Dealing

 

Oxford, UK - 7 October 2022: Oxford Biomedica plc ("Oxford Biomedica" or the
"Company") (LSE:OXB), a leading gene and cell therapy group, was informed that
Matthew Treagus, Chief Information Officer, has purchased 1,390 ordinary
shares of 50p each ("Ordinary Shares") in the Company on 7 October 2022 on the
London Stock Exchange at a price of 355.6655p. Following this purchase Matthew
Treagus holds 5,891 Ordinary Shares representing 0.00006% of the Company.

 

The below notification, made in accordance with the requirements of the EU
Market Abuse Regulation, gives further detail of the number of Ordinary Shares
purchased.

 

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")
 a)  Name                                     Matthew Treagus
 2.  Reason for the notification
 a)  Position/status                          Chief Information Officer

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Oxford Biomedica plc
 b)  LEI code                                 213800S1GVQNXQ15K851
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 50 pence each

     Identification code

                                              ISIN: GB00BDFBVT43
 b)  Nature of the transaction                Purchase
 c)  Price(s) and volumes(s)

Price(s)    Volume(s)
                                              £3.556655   1,390
 d)  Aggregated information

     ·      Aggregated volume                 1,390

     ·      Aggregated total

                                              £4,943.75

 e)  Date of the transaction                  07-10-2022
 f)  Place of the transaction                 London Stock Exchange, Main Market (XLON)

d)

Aggregated information

·      Aggregated volume

·      Aggregated total

 

 

1,390

 

£4,943.75

 

e)

Date of the transaction

07-10-2022

f)

Place of the transaction

London Stock Exchange, Main Market (XLON)

 

 

 

-Ends-

 

 For further information, please contact:

 Oxford Biomedica plc:                     Tel: +44 (0)1865 783 000

 Natalie Walter, Company Secretary

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist
focused on delivering life changing therapies to patients.

 

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral
vector delivery systems including those based on lentivirus, adeno-associated
virus (AAV) and adenovirus, providing innovative solutions to cell and gene
therapy biotechnology and biopharma companies for their process development,
analytical development and manufacturing needs. Oxford Biomedica has built a
sector leading lentiviral vector delivery system, LentiVector® platform, and
is working on programmes from pre-clinical to commercial stage across a range
of therapeutic areas with global partners.

 

Oxford Biomedica is based across several locations and headquartered in
Oxfordshire, UK. In 2022, the Group established Oxford Biomedica Solutions, a
US based subsidiary AAV manufacturing and innovation business, based near
Boston, US.

 

Further information is available at www.oxb.com (http://www.oxb.com) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBKOBBDBDDAKK